| Expression pattern: |
UP |
| Associated gene: |
IRTKS |
| Associated microRNA: |
- |
| Biological function: |
promotes GC cell proliferation and invasion; enhances tumor growth in vivo |
| Molecular mechanism: |
binds IRTKS protein and increases IRTKS protein stability (extends half-life), preventing degradation; IRTKS overexpression rescues phenotypes caused by circRNA_102231 knockdown |
| Biological pathway or process: |
proliferation (promotes); invasion (promotes); metastasis (promotes); other pathway/process (promotes) |
| Detected method: |
Q
|
| Validation methods: |
Bioinformatics Analysis; RT-qPCR; Clinical Sample Validation; CCK8; Colony Formation Assay; EdU Staining; Transwell Assay; RNA Pull-Down; RIP (RNA Immunoprecipitation); Western Blot; Transfection; In Vivo Animal Model; Survival Analysis; ROC Analysis |
| Clinical significance: |
High circRNA_102231 was associated with larger tumor volume, lymph node metastasis, higher clinical stage; high circRNA_102231 had shorter survival time; plasma circRNA_102231 showed diagnostic value (AUC 0.9032). |
| Description: |
circRNA_102231 is up-regulated in gastric cancer tissues and patient plasma and is associated with worse clinical outcomes. It promotes GC proliferation, invasion and tumor growth by binding the oncoprotein IRTKS and increasing its protein stability/half-life, and IRTKS overexpression rescues the effects of circRNA_102231 knockdown. |
| Confidence score: |
0.7793 |